252 related articles for article (PubMed ID: 31929500)
1. Well-Differentiated Papillary Mesothelioma with Omental Calcifications: A Case Report and Review of the Literature.
Erem AS; Allamaneni SS; Braverman TS
Am J Case Rep; 2020 Jan; 21():e920487. PubMed ID: 31929500
[TBL] [Abstract][Full Text] [Related]
2. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
Pisharodi LR; Bedrossian CW
Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
[TBL] [Abstract][Full Text] [Related]
3. Collagenous Spherulosis in Well-Differentiated Papillary Mesothelioma in a Female With Multilocular Peritoneal Inclusion Cysts.
AbdullGaffar B; Raman LG
Int J Surg Pathol; 2019 Jun; 27(4):427-431. PubMed ID: 30522362
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
5. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
[TBL] [Abstract][Full Text] [Related]
6. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
7. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
[TBL] [Abstract][Full Text] [Related]
8. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
9. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
10. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
11. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
Xing D; Banet N; Sharma R; Vang R; Ronnett BM; Illei PB
Hum Pathol; 2018 Feb; 72():160-166. PubMed ID: 29241740
[TBL] [Abstract][Full Text] [Related]
13. Well-differentiated papillary mesothelioma of the peritoneum: a diagnostic dilemma on fine-needle aspiration cytology.
Nasit JG; Dhruva G
Am J Clin Pathol; 2014 Aug; 142(2):233-42. PubMed ID: 25015866
[TBL] [Abstract][Full Text] [Related]
14. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases.
Malpica A; Sant'Ambrogio S; Deavers MT; Silva EG
Am J Surg Pathol; 2012 Jan; 36(1):117-27. PubMed ID: 22024662
[TBL] [Abstract][Full Text] [Related]
15. Diffuse Malignant Peritoneal Mesothelioma Presenting with Psammomatous Calcification on a Cervical Smear.
Tan A; Cohen P; Raoofi M; Tan J; Mesbah Ardakani N; Sterrett G
Acta Cytol; 2015; 59(6):498-504. PubMed ID: 26845517
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical profile of paratesticular serous papillary adenocarcinoma and tunica vaginalis facilitates distinction from malignant mesothelioma.
Anchala PR; Dhir R; Parwani AV; Zynger DL
Int J Surg Pathol; 2011 Oct; 19(5):692-8. PubMed ID: 19493919
[TBL] [Abstract][Full Text] [Related]
17. Combined adenomatoid tumor and well differentiated papillary mesothelioma of the omentum.
Hatano Y; Hirose Y; Matsunaga K; Kito Y; Yasuda I; Moriwaki H; Osada S; Yoshida K; Hara A
Pathol Int; 2011 Nov; 61(11):681-5. PubMed ID: 22029681
[TBL] [Abstract][Full Text] [Related]
18. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
[TBL] [Abstract][Full Text] [Related]
19. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
Chapel DB; Hirsch MS
Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic challenge of peritoneal mesothelioma.
Krasuski P; Poniecka A; Gal E
Arch Gynecol Obstet; 2002 Jul; 266(3):130-2. PubMed ID: 12197549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]